A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

Cancer Immunology, Immunotherapy

Volumn 52, Issue 4, 2003, Pages 243-248

  Chan, Stephen Y ^a   Gordon, Alan N ^b   Coleman, Robert E ^c   Hall, James B ^d   Berger, Mark S ^e   Sherman, Matthew L ^e   Eten, Catharine B ^e   Finkler, Neil J ^f  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b TEXAS ONCOLOGY   (United States)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d CAROLINAS MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

^f FLORIDA HOSPITAL   (United States)

Author keywords

Calicheamicin; CMB 401; Gemtuzumab ozogamicin; Hybrid linker; Ovarian carcinoma

Indexed keywords

ANTIBODY CONJUGATE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CALICHEAMICIN; CISPLATIN; CMB 401; CREATININE; GEMTUZUMAB OZOGAMICIN; HCTM01; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCTM01; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DYSPEPSIA; EPISTAXIS; EPITHELIUM CELL; EVALUATION; FEMALE; HEADACHE; HUMAN; MULTICENTER STUDY; MYALGIA; NAUSEA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REMISSION; RHINITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 0037733005     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0343-x     Document Type: Article

References (35)

1. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490
2. Clopper C, Pearson E (1934) The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika 26:404
3. Davies Q, Perkins AC, Roos JC, Molthoff CF, Verheijen RH, Frier M, Kenemans P, Broadhead T, Sopwith M, Symonds EM (1999) An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. British Journal of Obstet Gynaecol 106:31
4. de Vetten MP, Jansen JH, van der Reijden BA, Berger MS, Zijlmans JM, Lowenberg B (2000) Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol 111:277
5. Devine PL, McGuckin MA, Quin RJ, Ward BG (1994) Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same. Tumour Biol 15:337
6. Devine PL, McGuckin MA, Ramm LE, Harada H, Ward BG (1993) The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer. Cancer Biochem Biophys 13:221
7. De Voss JJ, Hangeland JJ, Townsend CA (1990) Characterization of the in vitro cyclization chemistry of calicheamicin and its relation to DNA cleavage. J Am Chem Soc 112:4554
8. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, McGuckin MA (1997) Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 183:3116
9. Gehan E (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Disord 13:346
10. Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M, Coleman RE (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjagate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol 11:735
11. Giuntoli RL 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA (1998) Mucin gene expression in ovarian cancers. Cancer Res 58:5546
12. Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KB, Ivey RT, Benbrook DM (2001) Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst 93:516
13. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40
14. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47
15. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53:3336
16. Ioannides CG, Fisk B, Jerome KR, Irimura T, Sharton JT, Finn Olivera J (1993) Cytotoxic T cells from ovarian malignant tumors can recognized polymorphic epithelial mucin core peptides. J Immunol 151:3693
17. McGuckin MA, Devine PL, Ramm LE, Ward BG (1994) Factors effecting the measurement of tumor-associated MUC1 mucins in serum. Tumour Biol 15:33
18. Miles DW, Taylor-Papadimitriou J (1999) Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma. Pharmacol Ther 82:97
19. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14:1436
20. Norum LF, Varaas T, Kierulf B, Nustad K (1998) Carcinoma-associated MUC1 detected by immunoradiometric assays. Tumour Biol 19:134
21. Petrarca C, Casalino B, von Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M (1999) Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 47:272
22. Pietersz GA, Wenjun L, Krauer K, Baker T, Wreschner D, McKenzie IF (1997) Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol Immunother 44:323
23. Prinssen HM, Molthoff CF, Verheijen RH, Broadhead TJ, Kenemans P, Roos JC, Davies Q, van Hof AC, Frier M, den Hollander W, Wilhelm AJ, Baker TS, Sopwith M, Symonds EM, Perkins AC (1998) Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol Immunother 47:39
24. Quin RJ, McGuckin MA (2000) Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion. Int J Cancer 87:499
25. Rabasseda X, Graul A, Castaner RM (2000) Gemtuzumab ozogamicin - treatment of acute myeloid leukemia. Drugs Future 25:686
26. Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J (2000) Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumour Biol 21:197
27. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678
28. Sievers EL, Larson RA, Estey E, L'wenberg B, Erba H, Gramatzki M, List A, Sierra J, Stadtmauer EA, Tarantolo S, Berger MS, Leopold LH, Eten C, Munteanu M, Stone A, Bernstein I, Appelbaum FR (2000) Preliminary report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with Mylotarg followed by hematopoietic stem cell transplantation [abstract]. J Immunother 23:607
29. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJM, Bernstein ID, Appelbaum FR (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244
30. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, van Zanten-Przybysz I, Hummel P, Nijman HW, Kenemans P, Hilgers J (1999) Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47
31. van der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen Jacques JM (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197
32. van Hof AC, Molthoff CF, Davies Q, Perkins AC, Verheijen RH, Kenemans P, den Hollander W, Wilhelm AJ, Baker TS, Sopwith M, Frier M, Symonds EM, Roos JC (1996) Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res 56:5179
33. Wyeth-Ayerst Research (2001) Data on file
34. Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198
35. Zein N, Poncin M, Nilakantan R, Ellestad GA (1989) Calicheamicin gamma II and DNA: molecular recognition process responsible for site-specificity. Science 244:697